ERS Genomics

ERS is the world leader in licensing CRISPR/Cas9 technology for a wide variety of applications.
Our founder, Dr. Emmanuelle Charpentier (the ‘E’in ERS) won the Nobel Prize for the discovery of CRISPR/Cas9 in 2020. 

Without question, CRISPR/Cas9 has transformed the field of gene editing. 
At ERS Genomics, our purpose is to extend global access to this technology and expand the boundaries of CRISPR potential.


BIO International is the perfect time to start or continue a conversation about your CRISPR license. We are excited to connect with companies who can benefit from our game-changing technology. A meeting or a call with us is worthwhile for you if:

You are interested in possible use of CRISPR/Cas9 for internal research programs:
– Are you using modified cells or animals from an academic source?
– Are you generating in-house reagents?


You are interested in use of genetically modified cells in manufacturing. Including… 
– mAbs
– Gene or cell therapy
– Vectors
– Industrial enyzmes or intermediates


You provide any services that use CRISPR/Cas9 or cells or animals modified by the technology. Including…
– High-throughput screening 
– Target identification, Target validation
– Cell line development
– Disease specific cell models
– Animal models of disease


You have an interest in animal health applications. Including… 
Disease resistance, Vaccines Trait improvements

Drop by our Booth, 2549, to connect or schedule a BIO Partnering meeting.


Schedule time with ERS

Jon Kratochvil


‘If you’re using or plan to use CRISPR/Cas9
technology, you need a License
from ERS Genomics.’

Connect with us @ Bio Boston in June.
Getting a license is easy, fast & flexible.

Jon Kratochvil, Vice President,  ERS Genonics.


Intellectual Property

Knowledge Centre

Contact US

Read More Of Our Articles

Explore more news on CRISPR/Cas9 and how it can provide a leading edge in the highly competitive biotech sector.

ERS Genomics & abm enter into CRISPR/Cas9 Licensing Agreement

ERS Genomics & abm enter into CRISPR/Cas9 Licensing Agreement This License allows abm to develop and commercialize products using CRISPR/Cas9 technology. Dublin, Ireland and Vancouver, Canada, 1st June 2023:  ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Applied Biological Materials Inc (‘abm,’). This is a.

Read Full Article

LSPN Boston 2023: Life Science IP Review

“Although CVC and Broad’s CRISPR/Cas9 gene editing patents currently coexist in the US, pending federal circuit appeal, the picture is clearer in the EPO opposition division which has affirmed the CVC foundational CRISPR patents over numerous opponents,” highlights Michael Arciero, VP, IP & Corporate Development

Read Full Article

BIO Europe, Basel 2023: Our thoughts

#BIO Europe is one of the most important Life Science events for people in the industry to attend. This year was no exception. ERS Senior Director, Dr. Ralph Vogelsang offers his thoughts on the recent Basle event in this quick read: https://lnkd.in/eET6s-rN

Read Full Article